{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:43:14Z","timestamp":1794472994706,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201700082C"],"award-info":[{"award-number":["HHSN272201700082C"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI105204"],"award-info":[{"award-number":["R01AI105204"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"Division of Intramural Research, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["2T32AI134646"],"award-info":[{"award-number":["2T32AI134646"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00930-z","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:02:23Z","timestamp":1723208543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Inactivated rabies-based Lassa fever virus vaccine candidate LASSARAB protects nonhuman primates from lethal disease"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-4791","authenticated-orcid":false,"given":"Gabrielle","family":"Scher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Yankowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3959-7700","authenticated-orcid":false,"given":"Drishya","family":"Kurup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.","family":"Josleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Steffens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginger","family":"Lynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Vantongeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-8755","authenticated-orcid":false,"given":"Xiankun","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Twenhafel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen A.","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9040-9405","authenticated-orcid":false,"given":"Matthias J.","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"930_CR1","first-page":"1","volume":"44","author":"O Ogbu","year":"2007","unstructured":"Ogbu, O., Ajuluchukwu, E. & Uneke, C. J. Lassa fever in West African sub-region: an overview. J. Vector Borne Dis. 44, 1\u201311 (2007).","journal-title":"J. Vector Borne Dis."},{"key":"930_CR2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/infdis\/155.3.437","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B., Webb, P. A., Krebs, J. W., Johnson, K. M. & Smith, E. S. A prospective study of the epidemiology and ecology of Lassa fever. J. Infect. Dis. 155, 437\u2013444, https:\/\/doi.org\/10.1093\/infdis\/155.3.437 (1987).","journal-title":"J. Infect. Dis."},{"key":"930_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.4269\/ajtmh.1983.32.829","volume":"32","author":"RA Keenlyside","year":"1983","unstructured":"Keenlyside, R. A. et al. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. Am. J. Trop. Med. Hyg. 32, 829\u2013837, https:\/\/doi.org\/10.4269\/ajtmh.1983.32.829 (1983).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"930_CR4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aau9343","volume":"363","author":"LE Kafetzopoulou","year":"2019","unstructured":"Kafetzopoulou, L. E. et al. Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. Science 363, 74\u201377, https:\/\/doi.org\/10.1126\/science.aau9343 (2019).","journal-title":"Science"},{"key":"930_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","volume":"311","author":"SP Fisher-Hoch","year":"1995","unstructured":"Fisher-Hoch, S. P. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. Bmj 311, 857\u2013859, https:\/\/doi.org\/10.1136\/bmj.311.7009.857 (1995).","journal-title":"Bmj"},{"key":"930_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-018-0049-5","volume":"3","author":"HJ Hallam","year":"2018","unstructured":"Hallam, H. J. et al. Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development. NPJ Vaccines 3, 11, https:\/\/doi.org\/10.1038\/s41541-018-0049-5 (2018).","journal-title":"NPJ Vaccines"},{"key":"930_CR7","doi-asserted-by":"publisher","first-page":"e2748","DOI":"10.1371\/journal.pntd.0002748","volume":"8","author":"JG Shaffer","year":"2014","unstructured":"Shaffer, J. G. et al. Lassa fever in post-conflict sierra leone. PLoS Negl. Trop. Dis. 8, e2748, https:\/\/doi.org\/10.1371\/journal.pntd.0002748 (2014).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"930_CR8","doi-asserted-by":"crossref","unstructured":"McCormick, J. B. & Fisher-Hoch, S. P. in Arenaviruses I: The Epidemiology, Molecular and Cell Biology of Arenaviruses (ed Michael B. A. Oldstone) 75\u2013109 (Springer Berlin Heidelberg, 2002).","DOI":"10.1007\/978-3-642-56029-3_4"},{"key":"930_CR9","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1001\/jama.1990.03450160063030","volume":"264","author":"D Cummins","year":"1990","unstructured":"Cummins, D. et al. Acute sensorineural deafness in Lassa fever. Jama 264, 2093\u20132096 (1990).","journal-title":"Jama"},{"key":"930_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/v4010083","volume":"4","author":"JH Nunberg","year":"2012","unstructured":"Nunberg, J. H. & York, J. The curious case of arenavirus entry, and its inhibition. Viruses 4, 83\u2013101, https:\/\/doi.org\/10.3390\/v4010083 (2012).","journal-title":"Viruses"},{"key":"930_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.antiviral.2016.08.012","volume":"133","author":"RW Cross","year":"2016","unstructured":"Cross, R. W. et al. Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies. Antivir. Res. 133, 218\u2013222, https:\/\/doi.org\/10.1016\/j.antiviral.2016.08.012 (2016).","journal-title":"Antivir. Res."},{"key":"930_CR12","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149, https:\/\/doi.org\/10.1038\/nm.4396 (2017).","journal-title":"Nat. Med."},{"key":"930_CR13","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses. PLoS Negl. Trop. Dis. 9, e0003736, https:\/\/doi.org\/10.1371\/journal.pntd.0003736 (2015).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"930_CR14","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1080\/21645515.2017.1356500","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever. Hum. Vaccin Immunother. 13, 2902\u20132911, https:\/\/doi.org\/10.1080\/21645515.2017.1356500 (2017).","journal-title":"Hum. Vaccin Immunother."},{"key":"930_CR15","doi-asserted-by":"publisher","unstructured":"Mateo, M. et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci. Transl. Med. 11 https:\/\/doi.org\/10.1126\/scitranslmed.aaw3163 (2019).","DOI":"10.1126\/scitranslmed.aaw3163"},{"key":"930_CR16","doi-asserted-by":"publisher","first-page":"11677","DOI":"10.1128\/jvi.75.23.11677-11685.2001","volume":"75","author":"P Pushko","year":"2001","unstructured":"Pushko, P., Geisbert, J., Parker, M., Jahrling, P. & Smith, J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75, 11677\u201311685, https:\/\/doi.org\/10.1128\/jvi.75.23.11677-11685.2001 (2001).","journal-title":"J. Virol."},{"key":"930_CR17","doi-asserted-by":"publisher","first-page":"6777","DOI":"10.1128\/jvi.74.15.6777-6783.2000","volume":"74","author":"SP Fisher-Hoch","year":"2000","unstructured":"Fisher-Hoch, S. P., Hutwagner, L., Brown, B. & McCormick, J. B. Effective vaccine for lassa fever. J. Virol. 74, 6777\u20136783, https:\/\/doi.org\/10.1128\/jvi.74.15.6777-6783.2000 (2000).","journal-title":"J. Virol."},{"key":"930_CR18","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1128\/jvi.79.22.13934-13942.2005","volume":"79","author":"IS Lukashevich","year":"2005","unstructured":"Lukashevich, I. S. et al. A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J. Virol. 79, 13934\u201313942, https:\/\/doi.org\/10.1128\/jvi.79.22.13934-13942.2005 (2005).","journal-title":"J. Virol."},{"key":"930_CR19","doi-asserted-by":"publisher","unstructured":"Carnec, X. et al. A Vaccine platform against arenaviruses based on a recombinant hyperattenuated mopeia virus expressing heterologous glycoproteins. J. Virol. 92 https:\/\/doi.org\/10.1128\/jvi.02230-17 (2018).","DOI":"10.1128\/jvi.02230-17"},{"key":"930_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.virol.2005.12.001","volume":"345","author":"PJ Bredenbeek","year":"2006","unstructured":"Bredenbeek, P. J. et al. A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345, 299\u2013304, https:\/\/doi.org\/10.1016\/j.virol.2005.12.001 (2006).","journal-title":"Virology"},{"key":"930_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00291-x","volume":"6","author":"RJ Fischer","year":"2021","unstructured":"Fischer, R. J. et al. ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. NPJ Vaccines 6, 32, https:\/\/doi.org\/10.1038\/s41541-021-00291-x (2021).","journal-title":"NPJ Vaccines"},{"key":"930_CR22","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183, https:\/\/doi.org\/10.1371\/journal.pmed.0020183 (2005).","journal-title":"PLoS Med."},{"key":"930_CR23","doi-asserted-by":"publisher","unstructured":"Jiang, J. et al. Multivalent DNA vaccines as a strategy to combat multiple concurrent epidemics: mosquito-borne and hemorrhagic fever viruses. Viruses 13 https:\/\/doi.org\/10.3390\/v13030382 (2021).","DOI":"10.3390\/v13030382"},{"key":"930_CR24","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1080\/21645515.2019.1616499","volume":"15","author":"J Jiang","year":"2019","unstructured":"Jiang, J. et al. Immunogenicity of a protective intradermal DNA vaccine against Lassa virus in cynomolgus macaques. Hum. Vaccin Immunother. 15, 2066\u20132074, https:\/\/doi.org\/10.1080\/21645515.2019.1616499 (2019).","journal-title":"Hum. Vaccin Immunother."},{"key":"930_CR25","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1080\/21645515.2017.1382780","volume":"13","author":"KA Cashman","year":"2017","unstructured":"Cashman, K. A. et al. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Hum. Vaccin Immunother. 13, 3010\u20133019, https:\/\/doi.org\/10.1080\/21645515.2017.1382780 (2017).","journal-title":"Hum. Vaccin Immunother."},{"key":"930_CR26","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3390\/vaccines1030262","volume":"1","author":"KA Cashman","year":"2013","unstructured":"Cashman, K. A. et al. Enhanced efficacy of a codon-optimized DNA vaccine encoding the glycoprotein precursor gene of Lassa Virus in a Guinea Pig Disease Model when delivered by dermal electroporation. Vaccines 1, 262\u2013277, https:\/\/doi.org\/10.3390\/vaccines1030262 (2013).","journal-title":"Vaccines"},{"key":"930_CR27","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.coviro.2020.09.003","volume":"44","author":"G Scher","year":"2020","unstructured":"Scher, G. & Schnell, M. J. Rhabdoviruses as vectors for vaccines and therapeutics. Curr. Opin. Virol. 44, 169\u2013182, https:\/\/doi.org\/10.1016\/j.coviro.2020.09.003 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"930_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06741-w","volume":"9","author":"T Abreu-Mota","year":"2018","unstructured":"Abreu-Mota, T. et al. Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever. Nat. Commun. 9, 4223, https:\/\/doi.org\/10.1038\/s41467-018-06741-w (2018).","journal-title":"Nat. Commun."},{"key":"930_CR29","unstructured":"India, C. T. R. Intramuscular inactiavted rabies vector platform Corona virus vaccine (rDNA-BBV151), http:\/\/ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=58694&EncHid=&userName=035425 (2021)."},{"key":"930_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1586\/14760584.2015.1011134","volume":"14","author":"A Giesen","year":"2015","unstructured":"Giesen, A., Gniel, D. & Malerczyk, C. 30 Years of rabies vaccination with Rabipur: a summary of clinical data and global experience. Expert Rev. Vaccines 14, 351\u2013367, https:\/\/doi.org\/10.1586\/14760584.2015.1011134 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"930_CR31","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1093\/infdis\/jiz332","volume":"220","author":"D Kurup","year":"2019","unstructured":"Kurup, D. et al. Inactivated rabies virus-based ebola vaccine preserved by vaporization is heat-stable and immunogenic against ebola and protects against rabies challenge. J. Infect. Dis. 220, 1521\u20131528, https:\/\/doi.org\/10.1093\/infdis\/jiz332 (2019).","journal-title":"J. Infect. Dis."},{"key":"930_CR32","doi-asserted-by":"publisher","first-page":"4093","DOI":"10.1016\/j.vaccine.2007.02.038","volume":"25","author":"R Carrion Jr.","year":"2007","unstructured":"Carrion, R. Jr. et al. A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity. Vaccine 25, 4093\u20134102, https:\/\/doi.org\/10.1016\/j.vaccine.2007.02.038 (2007).","journal-title":"Vaccine"},{"key":"930_CR33","doi-asserted-by":"publisher","first-page":"e1005276","DOI":"10.1371\/journal.ppat.1005276","volume":"11","author":"R Sommerstein","year":"2015","unstructured":"Sommerstein, R. et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog. 11, e1005276, https:\/\/doi.org\/10.1371\/journal.ppat.1005276 (2015).","journal-title":"PLoS Pathog."},{"key":"930_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/infdis\/jiab014","volume":"224","author":"D Kurup","year":"2021","unstructured":"Kurup, D. et al. Tetravalent rabies-vectored filovirus and Lassa Fever vaccine induces long-term immunity in nonhuman primates. J. Infect. Dis. 224, 995\u20131004, https:\/\/doi.org\/10.1093\/infdis\/jiab014 (2021).","journal-title":"J. Infect. Dis."},{"key":"930_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-020-00248-6","volume":"5","author":"D Kurup","year":"2020","unstructured":"Kurup, D., Wirblich, C., Ramage, H. & Schnell, M. J. Rabies virus-based COVID-19 vaccine CORAVAX\u2122 induces high levels of neutralizing antibodies against SARS-CoV-2. NPJ Vaccines 5, 98, https:\/\/doi.org\/10.1038\/s41541-020-00248-6 (2020).","journal-title":"NPJ Vaccines"},{"key":"930_CR36","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","volume":"214","author":"RF Johnson","year":"2016","unstructured":"Johnson, R. F. et al. An inactivated rabies virus-based Ebola vaccine, FILORAB1, adjuvanted with glucopyranosyl lipid A in stable emulsion confers complete protection in nonhuman primate challenge models. J. Infect. Dis. 214, S342\u2013s354, https:\/\/doi.org\/10.1093\/infdis\/jiw231 (2016).","journal-title":"J. Infect. Dis."},{"key":"930_CR37","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/infdis\/jir769","volume":"205","author":"H Behzad","year":"2012","unstructured":"Behzad, H. et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J. Infect. Dis. 205, 466\u2013473, https:\/\/doi.org\/10.1093\/infdis\/jir769 (2012).","journal-title":"J. Infect. Dis."},{"key":"930_CR38","doi-asserted-by":"publisher","first-page":"e930","DOI":"10.1097\/ccm.0000000000003967","volume":"47","author":"A Hernandez","year":"2019","unstructured":"Hernandez, A. et al. Phosphorylated hexa-acyl disaccharides augment host resistance against common nosocomial pathogens. Crit. Care Med. 47, e930\u2013e938, https:\/\/doi.org\/10.1097\/ccm.0000000000003967 (2019).","journal-title":"Crit. Care Med."},{"key":"930_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11544","volume":"7","author":"JE Robinson","year":"2016","unstructured":"Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544, https:\/\/doi.org\/10.1038\/ncomms11544 (2016).","journal-title":"Nat. Commun."},{"key":"930_CR40","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1016\/j.vaccine.2010.03.039","volume":"28","author":"N Johnson","year":"2010","unstructured":"Johnson, N., Cunningham, A. F. & Fooks, A. R. The immune response to rabies virus infection and vaccination. Vaccine 28, 3896\u20133901, https:\/\/doi.org\/10.1016\/j.vaccine.2010.03.039 (2010).","journal-title":"Vaccine"},{"key":"930_CR41","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1093\/infdis\/141.5.580","volume":"141","author":"PB Jahrling","year":"1980","unstructured":"Jahrling, P. B. et al. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J. Infect. Dis. 141, 580\u2013589, https:\/\/doi.org\/10.1093\/infdis\/141.5.580 (1980).","journal-title":"J. Infect. Dis."},{"key":"930_CR42","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","volume":"155","author":"KM Johnson","year":"1987","unstructured":"Johnson, K. M. et al. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155, 456\u2013464, https:\/\/doi.org\/10.1093\/infdis\/155.3.456 (1987).","journal-title":"J. Infect. Dis."},{"key":"930_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422x-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205, https:\/\/doi.org\/10.1186\/1743-422x-8-205 (2011).","journal-title":"Virol. J."},{"key":"930_CR44","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.3390\/v4102031","volume":"4","author":"NE Yun","year":"2012","unstructured":"Yun, N. E. & Walker, D. H. Pathogenesis of Lassa fever. Viruses 4, 2031\u20132048, https:\/\/doi.org\/10.3390\/v4102031 (2012).","journal-title":"Viruses"},{"key":"930_CR45","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/infdis\/155.3.465","volume":"155","author":"SP Fisher-Hoch","year":"1987","unstructured":"Fisher-Hoch, S. P. et al. Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J. Infect. Dis. 155, 465\u2013474, https:\/\/doi.org\/10.1093\/infdis\/155.3.465 (1987).","journal-title":"J. Infect. Dis."},{"key":"930_CR46","doi-asserted-by":"publisher","unstructured":"Cashman, K. A. et al. Immune-mediated systemic vasculitis as the proposed cause of sudden-onset sensorineural hearing loss following Lassa Virus exposure in cynomolgus macaques. mBio 9 https:\/\/doi.org\/10.1128\/mBio.01896-18 (2018).","DOI":"10.1128\/mBio.01896-18"},{"key":"930_CR47","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/infdis\/jiy641","volume":"219","author":"DX Liu","year":"2019","unstructured":"Liu, D. X. et al. Persistence of Lassa Virus associated with severe systemic arteritis in convalescing guinea pigs (Cavia porcellus). J. Infect. Dis. 219, 1818\u20131822, https:\/\/doi.org\/10.1093\/infdis\/jiy641 (2019).","journal-title":"J. Infect. Dis."},{"key":"930_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1073\/pnas.86.1.317","volume":"86","author":"SP Fisher-Hoch","year":"1989","unstructured":"Fisher-Hoch, S. P. et al. Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene. Proc. Natl Acad. Sci. USA 86, 317\u2013321, https:\/\/doi.org\/10.1073\/pnas.86.1.317 (1989).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"930_CR49","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/jci131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539\u2013551, https:\/\/doi.org\/10.1172\/jci131958 (2020).","journal-title":"J. Clin. Invest."},{"key":"930_CR50","doi-asserted-by":"publisher","first-page":"5959","DOI":"10.1016\/j.vaccine.2016.09.058","volume":"34","author":"KL Mansfield","year":"2016","unstructured":"Mansfield, K. L. et al. Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans. Vaccine 34, 5959\u20135967, https:\/\/doi.org\/10.1016\/j.vaccine.2016.09.058 (2016).","journal-title":"Vaccine"},{"key":"930_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00615-z","volume":"8","author":"C Yankowski","year":"2023","unstructured":"Yankowski, C., Kurup, D., Wirblich, C. & Schnell, M. J. Effects of adjuvants in a rabies-vectored Ebola virus vaccine on protection from surrogate challenge. NPJ Vaccines 8, 10, https:\/\/doi.org\/10.1038\/s41541-023-00615-z (2023).","journal-title":"NPJ Vaccines"},{"key":"930_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00532-7","volume":"7","author":"C Yankowski","year":"2022","unstructured":"Yankowski, C., Wirblich, C., Kurup, D. & Schnell, M. J. Inactivated rabies-vectored SARS-CoV-2 vaccine provides long-term immune response unaffected by vector immunity. NPJ Vaccines 7, 110, https:\/\/doi.org\/10.1038\/s41541-022-00532-7 (2022).","journal-title":"NPJ Vaccines"},{"key":"930_CR53","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1586\/14760584.2016.1140040","volume":"15","author":"CE Rupprecht","year":"2016","unstructured":"Rupprecht, C. E., Nagarajan, T. & Ertl, H. Current status and development of vaccines and other biologics for human rabies prevention. Expert Rev. Vaccines 15, 731\u2013749, https:\/\/doi.org\/10.1586\/14760584.2016.1140040 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"930_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jmv.1890370102","volume":"37","author":"JB McCormick","year":"1992","unstructured":"McCormick, J. B., Mitchell, S. W., Kiley, M. P., Ruo, S. & Fisher-Hoch, S. P. Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J. Med. Virol. 37, 1\u20137, https:\/\/doi.org\/10.1002\/jmv.1890370102 (1992).","journal-title":"J. Med. Virol."},{"key":"930_CR55","doi-asserted-by":"publisher","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl. Med. 13 https:\/\/doi.org\/10.1126\/scitranslmed.abf6348 (2021).","DOI":"10.1126\/scitranslmed.abf6348"},{"key":"930_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111094","volume":"40","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 40, 111094, https:\/\/doi.org\/10.1016\/j.celrep.2022.111094 (2022).","journal-title":"Cell Rep."},{"key":"930_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0042-6822(85)90440-4","volume":"140","author":"WH Wunner","year":"1985","unstructured":"Wunner, W. H., Dietzschold, B., Smith, C. L., Lafon, M. & Golub, E. Antigenic variants of CVS rabies virus with altered glycosylation sites. Virology 140, 1\u201312, https:\/\/doi.org\/10.1016\/0042-6822(85)90440-4 (1985).","journal-title":"Virology"},{"key":"930_CR58","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1084\/jem.152.1.99","volume":"152","author":"TJ Wiktor","year":"1980","unstructured":"Wiktor, T. J. & Koprowski, H. Antigenic variants of rabies virus. J. Exp. Med. 152, 99\u2013112, https:\/\/doi.org\/10.1084\/jem.152.1.99 (1980).","journal-title":"J. Exp. Med."},{"key":"930_CR59","doi-asserted-by":"publisher","first-page":"e1003389","DOI":"10.1371\/journal.ppat.1003389","volume":"9","author":"JE Blaney","year":"2013","unstructured":"Blaney, J. E. et al. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog. 9, e1003389, https:\/\/doi.org\/10.1371\/journal.ppat.1003389 (2013).","journal-title":"PLoS Pathog."},{"key":"930_CR60","first-page":"535","volume":"48","author":"JS Smith","year":"1973","unstructured":"Smith, J. S., Yager, P. A. & Baer, G. M. A rapid reproducible test for determining rabies neutralizing antibody. Bull. World Health Organ 48, 535\u2013541 (1973).","journal-title":"Bull. World Health Organ"},{"key":"930_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00464-2","volume":"7","author":"D Kurup","year":"2022","unstructured":"Kurup, D. et al. Measles-based Zika vaccine induces long-term immunity and requires NS1 antibodies to protect the female reproductive tract. NPJ Vaccines 7, 43, https:\/\/doi.org\/10.1038\/s41541-022-00464-2 (2022).","journal-title":"NPJ Vaccines"},{"key":"930_CR62","unstructured":"National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. 8th edn, (The National Academies Press, 2011)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00930-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00930-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00930-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T13:04:50Z","timestamp":1723208690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00930-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00930-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3673845\/v1","asserted-by":"object"}]},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"143"}}